Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

18.51 +0.55 (+3.06%)

Streaming Delayed Price Updated: 12:32 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Novocure Reports First Quarter 2026 Financial Results

April 30, 2026

From Novocure

Via Business Wire

Novocure to Report First Quarter 2026 Financial Results

April 01, 2026

From Novocure

Via Business Wire

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

March 26, 2026

From Novocure

Via Business Wire

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

March 02, 2026

From Novocure

Via Business Wire

Novocure to Participate in 2026 Leerink Global Healthcare Conference

February 27, 2026

From Novocure

Via Business Wire

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

February 26, 2026

From Novocure

Via Business Wire

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

February 24, 2026

From Novocure

Via Business Wire

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

February 11, 2026

From Novocure

Via Business Wire

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

January 12, 2026

From Novocure

Via Business Wire

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

From Novocure

Via Business Wire

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

December 01, 2025

From Novocure

Via Business Wire

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

November 26, 2025

From Novocure

Via Business Wire

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

November 12, 2025

From Novocure

Via Business Wire

Novocure Reports Third Quarter 2025 Financial Results

October 30, 2025

From Novocure

Via Business Wire

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

October 15, 2025

From Novocure

Via Business Wire

Novocure to Report Third Quarter 2025 Financial Results

October 01, 2025

From Novocure

Via Business Wire

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

September 29, 2025

From Novocure

Via Business Wire

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

September 15, 2025

From Novocure

Via Business Wire

Novocure Announces Upcoming Investor Events

August 28, 2025

From Novocure

Via Business Wire

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

August 25, 2025

From Novocure

Via Business Wire

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20, 2025

From Novocure

Via Business Wire

Novocure Reports Second Quarter 2025 Financial Results

July 24, 2025

From Novocure

Via Business Wire

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

July 01, 2025

From Novocure

Via Business Wire

Novocure to Report Second Quarter 2025 Financial Results

June 30, 2025

From Novocure

Via Business Wire

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025

From Novocure

Via Business Wire

Novocure Announces Upcoming Investor Events

May 27, 2025

From Novocure

Via Business Wire

Novocure Reports First Quarter 2025 Financial Results

April 24, 2025

From Novocure

Via Business Wire

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

April 23, 2025

From Novocure

Via Business Wire

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

April 22, 2025

From Novocure

Via Business Wire

Novocure to Report First Quarter 2025 Financial Results

April 01, 2025

From Novocure

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.